Clinical Trial Update: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tucatinib with oral etoposide and trastuzumab for metastatic HER2-positive breast cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Etoposide (Etoposide)
• HERCEPTIN (trastuzumab)
• Tukysa (tucatinib)

Snippet

Sponsor: Institut Curie | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING